# MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma

> **NCT03773744** · PHASE1 · WITHDRAWN · sponsor: **Turnstone Biologics, Corp.**

## Conditions studied

- Metastatic Melanoma
- Squamous Cell Skin Carcinoma

## Interventions

- **DRUG:** Ad-MAGEA3
- **DRUG:** MG1-MAGEA3
- **DRUG:** Pembrolizumab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03773744
- **Lead sponsor:** Turnstone Biologics, Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-15
- **Primary completion:** 2020-10-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** insufficient suitable drug supply
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03773744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03773744, "MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03773744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*